Beyond DNA: The unseen genome and novel omics approaches to PH

29 September 2021

  • days
  • Hours
  • Minutes

Chair and moderators

Micheala Aldred, Indiana University School of Medicine, USA

Vinicio de Jesus Perez, Stanford University, USA

Nicholas Morrell, University of Cambridge, UK


  • Francois Potus // MicroRNAs and IncRNAs in right heart hypertrophy and failure
  • Stephen Chen // LncRNA as biomarkers/therapeutic agents for pulmonary diseases - prospective view
  • Soni Savai-Pullamsetti // Epigenomics in pulmonary vascular remodelling
  • Herbert Schiller // Multiomic tools for single cell analysis
  • Christopher Rhodes // Proteomics: From discovery research toward the clinic - novel AI perspectives?

A deeper look

MicroRNAs and IncRNAs in right heart hypertrophy and failure

15:00-15:15 BST

Presenter: // Francois Potus, Laval University, Canada

Awaiting further information 


LncRNA as biomarkers/therapeutic agents for pulmonary diseases - prospective view

15:24-15:39 BST

Presenter: // Stephen Chan, University of Pittsburgh, USA

Over the past decade, appreciation has increased regarding the pervasive importance of non-coding RNA biology in controlling pulmonary vascular function and the pathogenic progression to pulmonary hypertension. While studies of microRNAs in PAH have dominated the literature, the biologic roles of long non-coding RNAs (lncRNAs) increasingly are emerging as pathogenic hubs of disease. Tens of thousands of lncRNA transcripts are encoded by the human genome. LncRNAs typically bind either proteins or other RNA molecules to enact epigenetic, transcriptional, and post-transcriptional regulation of gene expression, affecting a wide range of biological processes ranging from cell proliferation, apoptosis, and differentiation. While a number of lncRNAs have been reported as dysregulated in tissue and plasma of subjects with PAH, the actions of only a few lncRNAs thus far have been implicated in pulmonary vascular pathophysiology. As these discoveries advance, they open a door for development of specific lncRNAs as therapeutic targets in PAH. However, stemming from the number of unknowns that still exist in non-coding RNA biology, current technology for lncRNA inhibition may still need to advance in order to achieve true therapeutic performance – including minimizing off-target effects of lncRNA manipulation and ensuring cell-type specific delivery of such therapies. In this seminar, we will discuss the potential and limitations for therapeutic targeting of lncRNAs in pulmonary vascular disease. 


Epigenomics in pulmonary vascular remodelling

15:48-16:03 BST

Presenter: // Soni Savai-Pullamsetti, Max Planck Institute for Heart and Lung Research, Germany

Awaiting further information


Multiomic tools for single cell analysis

16:12-16:27 BST

Presenter: // Herbert Schiller, Helmholtz Zentrum München, Germany

Awaiting further information


Proteomics: From discovery research toward the clinic - novel AI perspectives?

16:36-16:51 BST

Presenter: // Christopher Rhodes, Imperial College London, UK

Recent genome-wide studies of both rare and common variation have brought greater clarity to the genetic architecture of pulmonary arterial hypertension and identified novel genes involved in disease development. Transcriptional signatures have been reported in peripheral circulating cells, whole lung tissue and pulmonary vascular cells. High-throughput plasma proteomics and metabolomics platforms have identified novel biomarkers associated with clinical outcomes, and can also provide molecular instruments for causality analyses. There are methodological challenges in particular for integrating these datasets, and statistical power limitations inherent to the study of a rare disease, but this strategy will, we expect reveal novel biomarkers and druggable targets, helping to open the way to personalised medicine in pulmonary hypertension. 

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI